A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?

Maria Domenica Cappellini, John B. Porter, Vip Viprakasit, Ali T. Taher

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Beta-thalassaemia causes defective haemoglobin synthesis leading to ineffective erythropoiesis, chronic haemolytic anaemia, and subsequent clinical complications. Blood transfusion and iron chelation allow long-term disease control, and haematopoietic stem cell transplantation offers a potential cure for some patients. Nonetheless, there are still many challenges in the management of beta-thalassaemia. The main treatment option for most patients is supportive care; furthermore, the long-term efficacy and safety of current therapeutic strategies are limited and adherence is suboptimal. An increasing understanding of the underlying molecular and cellular disease mechanisms plus an awareness of limitations of current management strategies are driving research into novel therapeutic options. Here we provide an overview of the current pathophysiology, clinical manifestations, and global burden of beta-thalassaemia. We reflect on what has been achieved to date, describe the challenges associated with currently available therapy, and discuss how these issues might be addressed by novel therapeutic approaches in development.

Original languageEnglish
Pages (from-to)300-311
JournalBlood Reviews
Volume32
Issue number4
DOIs
Publication statusPublished - 2018

Fingerprint

beta-Thalassemia
Therapeutics
Erythropoiesis
Hematopoietic Stem Cell Transplantation
Hemolytic Anemia
Blood Transfusion
Hemoglobins
Iron
Safety
Research

Keywords

  • Blood transfusion
  • Chronic haemolytic anaemia
  • Ineffective erythropoiesis
  • Iron overload
  • Novel therapies
  • Thalassaemia

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

A paradigm shift on beta-thalassaemia treatment : How will we manage this old disease with new therapies? / Cappellini, Maria Domenica; Porter, John B.; Viprakasit, Vip; Taher, Ali T.

In: Blood Reviews, Vol. 32, No. 4, 2018, p. 300-311.

Research output: Contribution to journalArticle

Cappellini, Maria Domenica ; Porter, John B. ; Viprakasit, Vip ; Taher, Ali T. / A paradigm shift on beta-thalassaemia treatment : How will we manage this old disease with new therapies?. In: Blood Reviews. 2018 ; Vol. 32, No. 4. pp. 300-311.
@article{8264cbdf5f9e4aeaa9dbea8a9f0e2623,
title = "A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?",
abstract = "Beta-thalassaemia causes defective haemoglobin synthesis leading to ineffective erythropoiesis, chronic haemolytic anaemia, and subsequent clinical complications. Blood transfusion and iron chelation allow long-term disease control, and haematopoietic stem cell transplantation offers a potential cure for some patients. Nonetheless, there are still many challenges in the management of beta-thalassaemia. The main treatment option for most patients is supportive care; furthermore, the long-term efficacy and safety of current therapeutic strategies are limited and adherence is suboptimal. An increasing understanding of the underlying molecular and cellular disease mechanisms plus an awareness of limitations of current management strategies are driving research into novel therapeutic options. Here we provide an overview of the current pathophysiology, clinical manifestations, and global burden of beta-thalassaemia. We reflect on what has been achieved to date, describe the challenges associated with currently available therapy, and discuss how these issues might be addressed by novel therapeutic approaches in development.",
keywords = "Blood transfusion, Chronic haemolytic anaemia, Ineffective erythropoiesis, Iron overload, Novel therapies, Thalassaemia",
author = "Cappellini, {Maria Domenica} and Porter, {John B.} and Vip Viprakasit and Taher, {Ali T.}",
year = "2018",
doi = "10.1016/j.blre.2018.02.001",
language = "English",
volume = "32",
pages = "300--311",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - A paradigm shift on beta-thalassaemia treatment

T2 - How will we manage this old disease with new therapies?

AU - Cappellini, Maria Domenica

AU - Porter, John B.

AU - Viprakasit, Vip

AU - Taher, Ali T.

PY - 2018

Y1 - 2018

N2 - Beta-thalassaemia causes defective haemoglobin synthesis leading to ineffective erythropoiesis, chronic haemolytic anaemia, and subsequent clinical complications. Blood transfusion and iron chelation allow long-term disease control, and haematopoietic stem cell transplantation offers a potential cure for some patients. Nonetheless, there are still many challenges in the management of beta-thalassaemia. The main treatment option for most patients is supportive care; furthermore, the long-term efficacy and safety of current therapeutic strategies are limited and adherence is suboptimal. An increasing understanding of the underlying molecular and cellular disease mechanisms plus an awareness of limitations of current management strategies are driving research into novel therapeutic options. Here we provide an overview of the current pathophysiology, clinical manifestations, and global burden of beta-thalassaemia. We reflect on what has been achieved to date, describe the challenges associated with currently available therapy, and discuss how these issues might be addressed by novel therapeutic approaches in development.

AB - Beta-thalassaemia causes defective haemoglobin synthesis leading to ineffective erythropoiesis, chronic haemolytic anaemia, and subsequent clinical complications. Blood transfusion and iron chelation allow long-term disease control, and haematopoietic stem cell transplantation offers a potential cure for some patients. Nonetheless, there are still many challenges in the management of beta-thalassaemia. The main treatment option for most patients is supportive care; furthermore, the long-term efficacy and safety of current therapeutic strategies are limited and adherence is suboptimal. An increasing understanding of the underlying molecular and cellular disease mechanisms plus an awareness of limitations of current management strategies are driving research into novel therapeutic options. Here we provide an overview of the current pathophysiology, clinical manifestations, and global burden of beta-thalassaemia. We reflect on what has been achieved to date, describe the challenges associated with currently available therapy, and discuss how these issues might be addressed by novel therapeutic approaches in development.

KW - Blood transfusion

KW - Chronic haemolytic anaemia

KW - Ineffective erythropoiesis

KW - Iron overload

KW - Novel therapies

KW - Thalassaemia

UR - http://www.scopus.com/inward/record.url?scp=85042086242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042086242&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2018.02.001

DO - 10.1016/j.blre.2018.02.001

M3 - Article

AN - SCOPUS:85042086242

VL - 32

SP - 300

EP - 311

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 4

ER -